RECRUITING

Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer

Description

This clinical trial studies barriers to genetic testing in African American men with prostate cancer and whether tailored, culturally relevant genetic testing education provided by a community-based health coach is beneficial in improving knowledge, attitudes, and awareness of genetic testing. Information gained from this study, may help researchers better understand and learn more about how to increase access to germline genetic testing in underrepresented populations.

Conditions

Prostate Carcinoma
Talk to us

Related Conditions:

Prostate Carcinoma

Study Overview

On this page

Study Details

Study overview

This clinical trial studies barriers to genetic testing in African American men with prostate cancer and whether tailored, culturally relevant genetic testing education provided by a community-based health coach is beneficial in improving knowledge, attitudes, and awareness of genetic testing. Information gained from this study, may help researchers better understand and learn more about how to increase access to germline genetic testing in underrepresented populations.

Navigate Study: Use of a Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African American Men With Prostate Cancer

Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer

Condition
Prostate Carcinoma
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age \>=18 years old.
  • 2. Able to speak and read in English.
  • 3. Have no known cancer risk genetic mutation.
  • 4. Self-identify as Black or African American.
  • 5. Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per National Comprehensive Cancer Network (NCCN) guidelines.
  • 1. Age \>=18 years old.
  • 2. Able to speak and read in English.
  • 3. Able to understand study procedures and to comply with them for the entire length of the study.
  • 4. Able to verbally consent.
  • 5. Self-identifies as Black or African-American.
  • 6. Self-reports a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer.
  • 1. Self-identifies as a medical oncologist or genetics provider.
  • 2. Able to speak and read in English.
  • 3. Able to understand study procedures and to comply with them for the entire length of the study.
  • 4. Able to verbally consent.
  • 1. Age \>=18 years old.
  • 2. Able to speak and read in English.
  • 3. Able to understand study procedures and to comply with them for the entire length of the study.
  • 4. Able to provide written informed consent.
  • 5. Have no known cancer risk genetic mutation.
  • 6. Self-identify as Black or African American.
  • 7. Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per NCCN guidelines.
  • 8. For patients recruited from the clinic: Presence of an oncology appointment within 3 months where germline testing will be discussed.
  • 1. Prior germline genetic test.
  • 2. Age \<18 years old.
  • 3. Unable to read or answer forms.
  • 1. Contraindication to any study-related procedure or assessment.
  • 1. Self-reports prior germline genetic test.
  • 2. Contraindication to any study-related procedure or assessment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Daniel Kwon, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2026-03-31